Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are anticipating strong performance driven by the continued success of Lilly's blockbuster treatments, particularly its insulin portfolio. However, there are also concerns about potential pressures from